First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for
expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.